NY-SERMO
16.3.2022 14:02:09 CET | Business Wire | Press release
A new survey from Sermo , a physician-first online community and leader in global HCP insights, found that physicians are facing a challenging onslaught of COVID-19 vaccine and treatment misinformation as reported by 3,600+ doctors around the world.
81% of physicians reported feeling that social media misinformation has caused an existential crisis in their profession. More than half (54%) of physicians surveyed reported that a patient has asked them for an unapproved COVID-19 treatment such as Ivermectin and Hydroxychloroquine. Also, more than half (55%) of physicians reported that COVID-19 vaccine misinformation is increasingly becoming an issue when meeting with patients.
Physicians are being bombarded with a variety of COVID-19 vaccine misinformation. The most common misinformation they are hearing from patients is that vaccine safety and effectiveness cannot be trusted because researchers rushed the development of the vaccine, reported by 60% of physicians.
Other types of misinformation heard by physicians from patients include:
- More than half (51%) of physicians reported hearing from patients that they don’t need a COVID-19 vaccine if they’ve already had Covid.
- Misinformation about vaccines modifying your DNA continues to prevail. 45% of physicians reported hearing this from patients.
- Conspiracy theories about microchips in vaccines have made their way to the doctor’s office as 29% of physicians reported hearing this from patients.
- 1 in 5 (20%) physicians reported hearing from patients that the COVID-19 vaccine gives you COVID-19.
- One-third of physicians (34%) reported hearing from patients that vaccines cause infertility. Physicians feel that vaccine hesitancy among pregnant women persists. 61% of physicians reported that pregnant patients are reluctant to get the vaccine.
- COVID-19 vaccine hesitancy is spilling over to other vaccines. 52% of surveyed physicians feel patients who have been hesitant to get COVID-19 vaccines will stop getting other vaccines.
“It’s clear from when we first launched the COVID-19 barometer at the start of the pandemic that misinformation is increasingly posing huge challenges to physicians when treating patients. Physicians feel like they are battling an infodemic that is threatening public health,” says Peter Kirk, Sermo CEO. “The barometer results clearly paint a picture that misinformation is showing up at appointments across the U.S. and the globe at a very local level.”
In addition to battling COVID-19 misinformation, surveyed physicians continue to report they are seeing a significant amount of reluctance among parents to get their kids vaccinated. 61% of physicians reported seeing patients more reluctant to vaccinate their children than themselves. Lack of long-term vaccine safety data in children (45%) was the leading reason physicians believed parents were reluctant to vaccinate their children. This is an increase from a previous Barometer survey fielded in November 2021 when 38% of physicians believed that lack of long-term vaccine safety data was keeping parents from vaccinating their children. 1 in 4 (23%) physicians believed that adverse effects and allergic reactions were a reason that parents weren’t vaccinating their children.
This survey was fielded as part 22 of Sermo’s COVID-19 Barometer and included more than 3,600 physician respondents between March 2 - March 3, 2022. To find out more about the findings of Sermo’s latest COVID-19 Real Time Barometer, visit app.sermo.com/covid19-barometer .
About Sermo:
Sermo turns physician experience, expertise, and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries, the company provides physicians with a social platform and unique community that fosters impactful peer-to-peer collaboration & discussions about issues that are important to them and their patients. Sermo offers on-demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners, and the medical community at large. To learn more, visit www.sermo.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005281/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 05:49:00 CEST | Press release
Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 19:16:00 CEST | Press release
Canadian-led expansion will build the world’s largest and most capable C-130 airtanker fleet Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
